Since 2017, the PD-1 (programmed cell death protein-1; CD279) inhibitor pembrolizumab is approved for treatment of mismatch repair-deficient cancers irrespective of the tumor site by the U.S. Food and Drug Administration [81,111]. Here, PDCD1 is linked to neoplasm.